Skip to main content

Table 1 Patient demographics and baseline characteristics (ITT population): post-hoc analysis

From: Efficacy and safety of ambrisentan in Chinese patients with connective tissue disease-pulmonary arterial hypertension: a post-hoc analysis

  Ambrisentan
CTD-PAH
(N = 71)
IPAH/HPAH
(N = 50)
Age (years), median (IQR) 40 (19–59) 40.6 (30–47)
Women, n (%) 69 (97.2) 36 (72.0)
Men 2 (2.8) 14 (28.0)
CTD medications, n (%)
 Hydroxychloroquine 29 (40.8)
 Glucocorticoids 51 (71.8)
 Immunosuppressants 27 (38.0)
BMI, kg/m2 21.2 (3.2) 22.2 (3.2)
6MWT, m 366.4 (60.4) 397.3 (48.1)
BDI score, n (%) 2.7 (1.3) 2.3 (1.5)
 Class II 32 (45.1) 31 (62.0)
 Class III 39 (54.9) 19 (38.0)
NT-ProBNP, ng/L 1837.5 (2209.6) 1281.3 (1140.6)
History of cardiovascular risk factors, n (%) 3 (4.2) 0
  1. BDI Borg Dyspnoea Index, BMI basal metabolic index, CTD connective tissue disease, HPAH Heritable PAH, IPAH Idiopathic PAH, IQR inter quartile range, ITT intent-to-treat, NT-ProBNP N-terminal pro hormone B-Type Natriuretic Peptide, 6MWT six-minute walk test
\